28 April 2010
The relative toxicity of compounds used as preservatives in vaccines and biologics
David A. GeierABCDEFG, Sarah K. JordanBE, Mark R. GeierABCDEFGMed Sci Monit 2010; 16(5): SR21-27 :: ID: 878526
Abstract
Background
In vaccines/biologics, preservatives are used to prevent microbial growth.
Material and Method
The present study examined: (1) the comparative toxicities of commonly used preservatives in US licensed vaccines to human neurons; and (2) the relative toxicity index of these compounds to human neurons in comparison to bacterial cells.
Results
Using human neuroblastoma cells, the relative cytotoxicity of the levels of the compounds commonly used as preservative in US licensed vaccines was found to be phenol <2-phenoxyethanol < benzethonium chloride < Thimerosal. The observed relative toxicity indices (human neuroblastoma cells/bacterial cells) were 2-phenoxyethanol (4.6-fold) < phenol (12.2-fold) < Thimerosal (>330-fold). In addition, for the compounds tested, except for 2-phenoxyethanol, the concentrations necessary to induce significant killing of bacterial cells were significantly higher than those routinely present in US licensed vaccine/biological preparations.
Conclusions
None of the compounds commonly used as preservatives in US licensed vaccine/biological preparations can be considered an ideal preservative, and their ability to fully comply with the requirements of the US Code of Federal Regulations (CFR) for preservatives is in doubt. Future formulations of US licensed vaccines/biologics should be produced in aseptic manufacturing plants as single dose preparations, eliminating the need for preservatives and an unnecessary risk to patients.
Keywords: Preservatives, Pharmaceutical - adverse effects, Cell Survival - drug effects, Escherichia coli - drug effects, Biological Products - adverse effects, Vaccines - adverse effects
Editorial
01 July 2026 : Editorial
Editorial: The WHO Identifies Ebola Disease Due to Bundibugyo Virus as a Public Health Emergency of International Concern (PHEIC) as Vaccine Development AcceleratesDOI: 10.12659/MSM.954627
Med Sci Monit 2026; 32:e954627
In Press
Clinical Research
Association of miR-133a With Microalbuminuria in Patients With Resistant Arterial Hypertension and Chronic ...Med Sci Monit In Press; DOI: 10.12659/MSM.952860
Clinical Research
Preliminary Application of Antihypertensive Gene Detection in the Treatment of HypertensionMed Sci Monit In Press; DOI: 10.12659/MSM.952296
Clinical Research
Effect of Low-Dose Vonoprazan on Hepatic Cytochrome P450 Activity By 13C-Aminopyrine Breath Test in Healthy...Med Sci Monit In Press; DOI: 10.12659/MSM.953332
Database Analysis
COVID-19 and Diabetes: Clinical Symptoms, Acute Kidney Injury, Inflammatory Response, and Poor Prognosis Fa...Med Sci Monit In Press; DOI: 10.12659/MSM.951864
Most Viewed Current Articles
17 Jan 2024 : Review article 14,175,888
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
13 Nov 2021 : Clinical Research 3,757,167
Acceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...DOI :10.12659/MSM.932788
Med Sci Monit 2021; 27:e932788
14 Dec 2022 : Clinical Research 2,466,050
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research 708,707
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387






